Sydney Jennings

Your daily dose of the clinical news you may have missed.

With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.

Your daily dose of the clinical news you may have missed.

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

FDA clears MiniMed 780G for integration with Abbott’s Instinct sensor and approves its use in insulin-requiring T2D, expanding automated insulin delivery options.

Your daily dose of the clinical news you may have missed.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

The FDA has accepted a New Drug Application for ensitrelvir, with a PDUFA action date set for June 16, 2026.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.

Your daily dose of the clinical news you may have missed.

Infectious disease and family medicine experts share guidance on vaccine policy changes, patient communication, and boosting vaccine confidence.

Your daily dose of the clinical news you may have missed.

Discover the latest advancements in atopic dermatitis treatment, including new topical agents and biologics, enhancing care for patients with moderate to severe conditions.

The FDA removed the prior requirement for a person who is already diagnosed with a cardiovascular disease.

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

Your daily dose of the clinical news you may have missed.

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Your daily dose of the clinical news you may have missed.

Infectious disease expert shares strategies for PCPs to counter vaccine myths, navigate policy changes, and build patient trust.

AbbVie reports that upadacitinib met primary and secondary endpoints, with up to 55% of patients achieving at least 80% scalp hair coverage at 24 weeks.

Your daily dose of the clinical news you may have missed.

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses challenges to diagnosing and treating venous disease in patients with obesity.

Vaginal estradiol is often prescribed as first-line therapy for genitourinary syndrome of menopause, making the findings supportive of current clinical practice.

Your daily dose of the clinical news you may have missed.